يعرض 161 - 180 نتائج من 43,954 نتيجة بحث عن '(((( 50 ((nn decrease) OR (we decrease)) ) OR ( 09 0 decrease ))) OR ( 50 a decrease ))', وقت الاستعلام: 0.64s تنقيح النتائج
  1. 161
  2. 162
  3. 163
  4. 164

    Supplementary Material for: Platelet Decreases following Continuous Renal Replacement Therapy Initiation as a Novel Risk Factor for Renal Nonrecovery حسب Griffin B.R. (8570007)

    منشور في 2021
    "…<b><i>Results:</i></b> Time to RRT independence censored for death was achieved less frequently in patients with low platelet nadir (hazard ratio [HR] 0.77, confidence interval [CI] 0.66–0.91) and in those with >50% platelet decrease (HR 0.84, CI 0.72–0.97). RRT-free days were lower in both low platelet nadir (odds ratio [OR] 0.94, CI 0.90–0.97) and >50% platelet decrease (OR 0.91, CI 0.88–0.95). …"
  5. 165
  6. 166

    Table_1_Decreasing the carbon footprint of food through public procurement—A case study from the municipality of Härnösand.XLSX حسب Mari Kjellberg (20130183)

    منشور في 2024
    "…This study examines alternative purchase processes that may decrease the carbon footprint of publicly procured food through a case study of a municipality in the Northern part of Sweden. …"
  7. 167

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation حسب Kairui Yue (11874403)

    منشور في 2022
    "…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…"
  8. 168

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation حسب Kairui Yue (11874403)

    منشور في 2022
    "…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…"
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179

    Differences among the classes of CAMs. حسب Daniel P. Bradley (10306893)

    منشور في 2025
    "…Some <i>N</i>-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …"
  20. 180